8-K current report · filed Jul 30, 2026

ANAPTYSBIO, INC (ANAB) 8-K Current Report: July 30, 2026

Item 7.01ANAB overview

Short answer

ANAPTYSBIO, INC (ANAB) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 7.01 (Regulation FD Disclosure). Delaware Chancery litigation remains unresolved after July 14-17, 2026 trial.

ANAPTYSBIO, INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Delaware Chancery litigation remains unresolved after July 14-17, 2026 trial
  • AnaptysBio alleges Tesaro breached the collaboration agreement and GSK tortiously interfered
  • Post-trial briefing schedule extends through October 9, 2026
  • Post-trial argument scheduled for October 20, 2026
  • Outcome could affect AnaptysBio’s collaboration rights and potential litigation-related recovery or exposure

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ANAPTYSBIO, INC 8-K filings

Get the next ANAB 8-K as it lands

Follow ANAB for push alerts, or ask the research agent what this filing means.